DENTSPLY SIRONA Inc. - 10-Q Summary (Q3 2024)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. DENTSPLY SIRONA Inc. is the world's largest manufacturer of professional dental products and technologies, operating through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company is currently navigating macroeconomic headwinds, legislative changes affecting its direct-to-consumer aligner business, and ongoing legal proceedings.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales | $951 | $947 | $2,888 | $2,953 |
| Gross Profit | $495 | $495 | $1,512 | $1,564 |
| Gross Margin | 52.1% | 52.2% | 52.4% | 53.0% |
| Operating Loss | $(462) | $(236) | $(370) | $(158) |
| Net Loss | $(495) | $(266) | $(482) | $(204) |
| Diluted EPS | $(2.46) | $(1.25) | $(2.35) | $(0.94) |
| Cash from Operations (9M) | $374 | $217 | - | - |
| Total Debt (Current + Long-term) | $2,217 | - | - | - |
| Cash & Equivalents | $296 | - | - | - |
Material Changes vs. Prior Period
- Impairment Charges: The company recorded a significant $504 million pre-tax goodwill impairment charge in Q3 2024 (vs. $307 million in Q3 2023). This was driven by the Orthodontic Aligner Solutions ($145 million) and Implant & Prosthetic Solutions ($359 million) reporting units. A separate $6 million intangible asset impairment was recorded in Q1 2024.
- Revenue Trends: Net sales were flat in Q3 2024 (+0.5%) but declined 2.2% for the nine-month period. Organic sales grew 1.3% in Q3 but declined 1.0% for the nine months, primarily due to weaker demand in Connected Technology Solutions and Orthodontic/Implant segments.
- Restructuring: Restructuring costs increased to $23 million in Q3 2024 (vs. $6 million in Q3 2023) due to a new plan approved in July 2024 targeting a 2-4% global workforce reduction.
- Segment Performance: Essential Dental Solutions saw organic sales growth of 7.5% in Q3. Conversely, Connected Technology Solutions and Orthodontic and Implant Solutions faced declines due to competitive pricing, legislative impacts on teledentistry, and macroeconomic pressures.
Guidance, Outlook, and Risks
- Byte Aligner Suspension: On October 24, 2024, the company voluntarily suspended sales and marketing of its Byte direct-to-consumer aligner system and impression kits pending a regulatory review with the FDA. This business represented approximately 5% of revenue for the nine months ended September 30, 2024. Management expects a material adverse impact on future results and potential further asset impairments.
- Geopolitical Risks: Ongoing conflicts in Israel and Ukraine continue to pose risks. While operations in Israel remain open, there are risks of disruption. In Russia, currency controls limit the repatriation of approximately $40 million in cash, and European banking restrictions are reducing the ability to receive intercompany payments.
- Legal Proceedings: The company is facing multiple securities class actions and derivative suits related to revenue recognition and distributor inventory levels from 2021-2022. An IRS examination regarding a 2016 internal reorganization is also ongoing, with a proposed adjustment that could impact foreign tax credits.
- Outlook: Management anticipates continued inflationary pressure on raw materials and wages. The company expects to maintain R&D investment at at least 4% of annual net sales. Capital expenditures for 2024 are estimated between $170 million and $200 million.
Investor Verification Checklist
- Byte Aligner Impact: Verify the timeline for the regulatory review and the potential for permanent discontinuation of the direct-to-consumer aligner business model.
- Goodwill Valuation: Assess the remaining $814 million goodwill balance in the Implant & Prosthetic Solutions unit, which is currently trading near its carrying value and remains sensitive to further declines in demand or margin assumptions.
- Liquidity in Russia: Monitor the status of the $40 million cash trapped in Russia and the potential for further banking restrictions that could force a suspension of operations.
- Legal Exposure: Track the progress of the securities litigation and the IRS dispute, as unfavorable outcomes could result in significant damages or tax liabilities.
- Restructuring Execution: Confirm the realization of the targeted $80-$100 million in annual cost savings from the 2024 restructuring plan.